ArticleInformatics in medicine unlocked2020
Engineering a novel subunit vaccine against SARS-CoV-2 by exploring immunoinformatics approach.
Article in Informatics in medicine unlocked, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- An Immunoinformatic Approach for a Multi-Epitope Vaccine Against Toxoplasma gondii.Parasite immunology · 2026Article
- Designing of a conserved subunit multiepitope vaccine candidate against Francisella tularensis Schu S4 using immunoinformatics.Scientific reports · 2026Article
- Designing of an innovative conserved multiepitope subunit vaccine targeting SARS-CoV-2 glycoprotein and nucleoprotein through immunoinformatic.Scientific reports · 2025Article
- Designing a Multi-Epitope Vaccine Against HPV 16, 18, 33, and 45 Targeting L1 and E7 Proteins: An Immunoinformatics Approach for Cervical Cancer Prevention and Therapy.Bioinformatics and biology insights · 2025Article
- Novel SARS-COV2 poly epitope phage-based candidate vaccine and its immunogenicity.Research in pharmaceutical sciences · 2024Article
- Insights into structural vaccinology harnessed for universal coronavirus vaccine development.Clinical and experimental vaccine research · 2024Review
- Exploring malaria parasite surface proteins to devise highly immunogenic multi-epitope subunit vaccine for Plasmodium falciparum.Journal, genetic engineering & biotechnology · 2024Article
- DNA Vaccines: Their Formulations, Engineering and Delivery.Vaccines · 2024Review
- Proteome based analysis of circulating SARS-CoV-2 variants: approach to a universal vaccine candidate.Genes & genomics · 2023Article
- Mapping Potential Vaccine Candidates Predicted by VaxiJen for Different Viral Pathogens between 2017-2021-A Scoping Review.Vaccines · 2022Article
- Designing a Multi-Epitope Vaccine againstVaccines · 2022Article
- Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach.Molecular biotechnology · 2022Article
- SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways.Expert review of vaccines · 2022Review
- Mining of Marburg Virus Proteome for Designing an Epitope-Based Vaccine.Frontiers in immunology · 2022Article
- Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines.Immunological investigations · 2021Review
- An in-depth in silico and immunoinformatics approach for designing a potential multi-epitope construct for the effective development of vaccine to combat against SARS-CoV-2 encompassing variants of concern and interest.Computers in biology and medicine · 2021Article
- Current and prospective computational approaches and challenges for developing COVID-19 vaccines.Advanced drug delivery reviews · 2021Review
- Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.iScience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the number of infections and deaths caused by the recent COVID-19 pandemic is increasing dramatically day-by-day, scientists are rushing towards developing possible countermeasures to fight the deadly virus, SARS-CoV-2. Although many efforts have already been put forward for developing potential vaccines; however, most of them are proved to possess negative consequences. Therefore, in this study, immunoinformatics methods were exploited to design a novel epitope-based subunit vaccine against the SARS-CoV-2, targeting four essential proteins of the virus i.e., spike glycoprotein, nucleocapsid phosphoprotein, membrane glycoprotein, and envelope protein. The highly antigenic, non-allergenic, non-toxic, non-human homolog, and 100% conserved (across other isolates from different regions of the world) epitopes were used for constructing the vaccine. In total, fourteen CTL epitopes and eighteen HTL epitopes were used to construct the vaccine. Thereafter, several
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.